New imaging agent could light up rare tumors
NCT ID NCT05636540
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing an investigational radioactive tracer called 18F-FluorThanatrace (FTT) for PET/CT scans in up to 30 people with pheochromocytoma or paraganglioma—rare tumors of the adrenal glands or nerve tissue. The tracer aims to measure a protein called PARP-1 in the tumors. Importantly, the scan results will not be used to guide treatment; this is purely an observational study to see if the tracer can effectively highlight these tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-FluorThanatrace ([18F]FTT) - an investigational radioactive tracer for PET/CT imaging
What this could lead to
If successful, this could lead to a new imaging method to better see and understand these rare tumors, potentially helping future treatment decisions.
What could go wrong
This is a very early, small study (30 people) that is purely observational—it won't change treatment. The tracer may not reliably highlight tumors, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States